Olin Posts 7 Percent Revenue Rise in Q2

Olin (NYSE:OLN) reported mixed Q2 2025 results, with revenue of $1,758.3 million exceeding estimates by 6.0% year-over-year, driven by growth across all segments. However, profitability significantly deteriorated, with GAAP EPS turning negative at ($0.01), missing expectations of a $0.01 profit and sharply down from $0.62 a year prior. Adjusted EBITDA also declined 36.6% to $176.1 million. This profit pressure stemmed from rising input costs, scheduled maintenance expenses, and persistent weakness in key end-markets, leading to sharp earnings declines in the Chlor Alkali, Epoxy, and Winchester segments despite revenue growth. The company expects little sequential improvement in Q3 2025, guiding adjusted EBITDA between $170 million and $210 million, reflecting continued challenging market conditions and cost pressures.

Analysis

Olin's second-quarter 2025 results present a stark contrast between topline growth and deteriorating profitability. While revenue increased 7.0% year-over-year to $1,758.3 million, beating estimates by 6.0%, the company's bottom line suffered a significant decline. GAAP EPS swung to a loss of ($0.01) from a $0.62 profit a year earlier, and adjusted EBITDA fell 36.6% to $176.1 million. This margin compression was pervasive across all business segments, driven by a combination of rising input costs, scheduled maintenance expenses, and persistent market weakness. The Chlor Alkali division saw earnings fall 34.6% due to lower pricing for products like ethylene dichloride. The Epoxy segment reported a deeper operating loss, pressured by global oversupply and aggressive competition. Most notably, the Winchester ammunition segment experienced an approximate 64% drop in earnings despite a 10.3% rise in sales, as strong military shipments were insufficient to offset weak commercial demand, retailer destocking, and escalating raw material costs. Consequently, leverage has increased, with the net debt to adjusted EBITDA ratio rising to 3.9 times. Management's guidance for Q3 adjusted EBITDA of $170 million to $210 million signals that these challenging conditions are expected to persist in the near term.

Key Decisions for Investors

• Investors should recognize that the positive 7.0% revenue growth is being completely overshadowed by severe margin compression across all segments, a trend management expects to continue into Q3 with its subdued EBITDA guidance.
• It is critical to monitor input costs for chemicals and metals, as well as pricing for key products like ethylene dichloride, as these factors were the primary drivers of the 36.6% decline in adjusted EBITDA.
• While the Winchester segment's military contracts provide a revenue backstop, the ~64% collapse in its earnings demonstrates significant vulnerability to cyclical commercial demand and inflation, making it a key area of risk.
• Given the rise in leverage to 3.9x net debt to adjusted EBITDA, scrutinize the sustainability of the dividend and share repurchase programs if profitability does not recover, despite management's current commitment.